Editor’s ChoiceAcademic JournalMain Category: Asbestos / MesotheliomaAlso Included In: Lung CancerArticle Date: 01 Jun 2012 – 7:00 PDT
Current ratings for:’Mesothelioma – Photodynamic Therapy Yields Longer Survival Rates’
Treating patients with malignant pleural mesothelioma with PDT (photodynamic therapy) alongside lung-sparing surgery appears to result in significantly longer survival rates – up to two years longer compared to other treatments, and sometimes even more, researchers from the Perelman School of Medicine, University of Pennsylvania reported in Annals of Thoracic Surgey.
Mesothelioma is an extremely aggressive form of cancer and is typically caused by asbestos exposure. Experts state it is one of the deadliest forms of cancer. Asbestos exposure can result in the development of cancer 10 to 15 years later. However, only about 4 in every 10 patients survive more than a year after mesothelioma diagnosis.
Lead author, Joseph Friedberg, MD, said:
“While I do not think about anything short of a cure as a victory against mesothelioma, I am encouraged by our results. Based on our new findings, we are redoubling our clinical and translational research efforts to find a way to further improve and refine this multimodality treatment approach for mesothelioma.”
In a previous study, the same team had shown that lung-sparing surgery plus photodynamic therapy was better for patients with mesothelioma than traditional treatment. Traditional treatment involved surgically removing a lung, whole chest radiation and chemotherapy.
38 patients, all of them with mesothelioma, underwent lung-sparing surgery and photodynamic therapy. In each case, a specialist decided whether they were suitable for lung-sparing surgery. All but one of them had advanced stage (III/IV) cancer. When they were followed up 34 months after the PDT plus lung-sparing surgery, the median overall survival rate was 31.7 months.
In 31 of the patients, the subtype of the cancer was a significant factor, the authors added. They had the epithelial subtype – and their median overall survival was 41.2 months.
The authors explain that with mesothelioma patients, oncologists focus on extending their lives and improving quality of life. All patients with this type of cancer eventually experience recurrence – the cancer comes back. If the patient can keep both lungs, they are in a better position to withstand additional treatment when the cancer comes back, and consequently live longer.
A beam of light travels along fiber optics for photodynamic therapy. The patient is given a photosensitive drug that is absorbed by cancer cells. The light beam is aimed at the tumor site, which activates the drugs, and destroys cancer cells
“We are working together as a team, not just in the clinic but in the laboratory as well, to find the ideal way to combine our respective expertise. Our goal is an innovative combined treatment that represents a new level of a multipronged attack on this horrendous cancer.”
Copyright: Medical News TodayNot to be reproduced without permission of Medical News Today Visit our asbestos / mesothelioma section for the latest news on this subject. Friedberg, Joseph S., Culligan, Melissa J., Mick, Rosemarie, Stevenson, James, Hahn, Stephen M., Sterman, Daniel, Punekar, Salman, Glatstein, Eli, Cengel, Keith”Radical Pleurectomy and Intraoperative Photodynamic Therapy for Malignant Pleural Mesothelioma”Ann Thorac Surg 2012 93: 1658-1667 Please use one of the following formats to cite this article in your essay, paper or report:
. “Mesothelioma – Photodynamic Therapy Yields Longer Survival Rates.” Medical News Today. MediLexicon, Intl., 1 Jun. 2012. Web.1 Jun. 2012. <http://www.medicalnewstoday.com/articles/246104.php>
Please note: If no author information is provided, the source is cited instead.
‘Mesothelioma – Photodynamic Therapy Yields Longer Survival Rates’
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
For any corrections of factual information, or to contact the editors please use our feedback form.Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
- Antidepressant eases radiation-related mouth pain in head, neck cancer
- Two-Drug NSCLC Therapy Can’t Boost Survival (CME/CE)
- Saving a penny: Stem cell therapy shows promise in repairing stress urinary incontinence
- Clinical Notes: European Panel OKs Gene Therapy
- FDA clears MEVION S250 Proton Therapy System
- Prostate Cancer Patients Fare Better On Continuous Hormone Therapy When Compared With Intermittent Hormone Therapy
- Intermittent hormone therapy for prostate cancer inferior to continuous therapy
- Smoker’s genetic makeup can help predict response to drug therapy
- Diabetes drug could be a promising therapy for traumatic brain injury
- Managing Prostate Cancer With Focal Therapy
Submited at Friday, June 1st, 2012 at 4:00 pm on Uncategorized by Gillan
Comment RSS 2.0 - leave a comment - trackback